PPLPHARMA.NSPPLPHARMA.NSNSE
Loading
EBITDA Over TimeStable
Percentile Rank100
3Y CAGR+3.7%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+3.7%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
1.1x
Modest growth
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
2025$14.04B+2.7%
2024$13.67B+61.5%
2023$8.46B-32.8%
2022$12.60B-2.9%
2021$12.97B-